Details for New Drug Application (NDA): 209819
✉ Email this page to a colleague
The generic ingredient in SUBLOCADE is buprenorphine. There are twenty-nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the buprenorphine profile page.
Summary for 209819
Tradename: | SUBLOCADE |
Applicant: | Indivior |
Ingredient: | buprenorphine |
Patents: | 12 |
Pharmacology for NDA: 209819
Mechanism of Action | Partial Opioid Agonists |
Medical Subject Heading (MeSH) Categories for 209819
Suppliers and Packaging for NDA: 209819
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819 | NDA | Indivior Inc. | 12496-0100 | 12496-0100-1 | 1 POUCH in 1 CARTON (12496-0100-1) / 1 SYRINGE in 1 POUCH (12496-0100-2) / 1 SOLUTION in 1 SYRINGE (12496-0100-5) |
SUBLOCADE | buprenorphine | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | 209819 | NDA | Indivior Inc. | 12496-0300 | 12496-0300-1 | 1 POUCH in 1 CARTON (12496-0300-1) / 1 SYRINGE in 1 POUCH (12496-0300-2) / 1 SOLUTION in 1 SYRINGE (12496-0300-5) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | Strength | 100MG/0.5ML (100MG/0.5ML) | ||||
Approval Date: | Nov 30, 2017 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jun 6, 2031 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jun 25, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Jun 6, 2031 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER |
Complete Access Available with Subscription